This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00130728
First received: August 12, 2005
Last updated: July 12, 2017
Last verified: July 2017
  Purpose
This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.

Condition Intervention Phase
Non-Small Cell Lung Cancer Drug: bevacizumab Drug: erlotinib HCl Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy

Resource links provided by NLM:


Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Overall Survival (OS) Among All Randomized Patients [ Time Frame: From the date of randomization until the date of patient death from any cause, or the date of last contact. (Up to 3.1 years) ]
    Overall Survival was defined as the period from the date of randomization until the date of patient death from any cause. For patients who had not died, survival data was censored at the date of last contact.


Secondary Outcome Measures:
  • Progression-free Survival (PFS) [ Time Frame: From randomization to documented disease progression or death on study treatment, whichever occurred first. (Up to 3.1 years) ]
    PFS was defined as the time from randomization to documented disease progression, as determined by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST), or death on study treatment, whichever occurred first.

  • Percentage of Participants With Objective Response [ Time Frame: The median duration of Objective response was up to 9.7 months ]
    Objective response was defined as a complete or partial response determined by RECIST on two consecutive occasions >= 4 weeks apart.

  • Duration of Objective Response [ Time Frame: Period from Objective response until disease progression or death on study treatment. (Up to 29.5 months) ]
    Duration of objective response was defined as the period from the date of the initial partial or complete response until the date of disease progression or death on study treatment from any cause. For patients who had not died, data was censored at the date of last contact.


Enrollment: 636
Actual Study Start Date: June 8, 2005
Estimated Study Completion Date: December 31, 2017
Primary Completion Date: July 15, 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: erlotinib HCl + bevacizumab
oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
Drug: bevacizumab
intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
Placebo Comparator: erlotinib HCl + placebo
oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
Drug: erlotinib HCl
oral erlotinib HCl 150 mg/day orally
Drug: placebo
intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • Cytologically or histologically confirmed NSCLC
  • Clinical or radiographic progression during or after first-line chemotherapy or chemoradiotherapy for NSCLC
  • Consent to provide archival tissue for analysis is required for participation in this study
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Age ≥ 18 years
  • Use of an acceptable means of contraception for men and women of childbearing potential
  • International normalized ratio (INR) no greater than 1.3 and an aPTT no greater than the upper limits of normal within 28 days prior to enrollment for patients not on low‑molecular‑weight heparin or fondaparinux

Exclusion Criteria:

  • Squamous cell carcinoma
  • Prior treatment with an investigational or marketed inhibitor of the Epidermal Growth Factor Receptor (EGFR) pathway or anti-angiogenesis agent
  • Systemic chemotherapy, radiotherapy, or investigational treatment within 28 days prior to randomization
  • Local palliative radiotherapy within 14 days prior to randomization or persistent adverse effects from radiotherapy that have not resolved to Grade 2 or less following completion of treatment
  • Whole brain radiotherapy or stereotactic radiosurgery for brain metastases within 4 weeks of Day 0
  • Neurosurgery for brain metastases within 24 weeks of Day 0
  • Brain biopsy within 12 weeks of Day 0
  • Current use of dexamethasone for treatment associated with brain metastases
  • History of gross hemoptysis within 3 months prior to randomization unless definitively treated with surgery or radiation
  • History of any of the following within 6 months prior to Day 0: serious systemic disease, uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) Grade 2 or greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
  • Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior to randomization
  • Central Nervous System (CNS) bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic) within the last 6 months
  • Progressive neurologic symptoms in patients with a history of brain metastases
  • Full-dose anticoagulation with warfarin
  • Chronic daily use of aspirin or other full-dose nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-platelet activity
  • In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
  • Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior to randomization
  • Anticipation of need for a major surgical procedure during the course of the study
  • Serious, non-healing wound, ulcer, or bone fracture
  • Inability to take oral medication or requirement for intravenous (IV) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption
  • Pregnancy or breast-feeding
  • Presence of another invasive cancer within 5 years prior to randomization
  • Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Informed Consent Form or their ability to comply with study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00130728

Locations
United States, California
Kaiser Permanente - Vallejo
Vallejo, California, United States, 94589
United States, Georgia
University Cancer & Blood Center, LLC
Athens, Georgia, United States, 30607
United States, Maryland
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr
Annapolis, Maryland, United States, 21401
United States, Missouri
University of Kansas Medical Center
Kansas City, Missouri, United States, 64131
Sponsors and Collaborators
Genentech, Inc.
Investigators
Study Director: Clinical Trials Genentech, Inc.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00130728     History of Changes
Other Study ID Numbers: OSI3364g
Study First Received: August 12, 2005
Results First Received: November 16, 2009
Last Updated: July 12, 2017

Keywords provided by Genentech, Inc.:
NSCLC
Avastin
Tarceva
Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Bevacizumab
Erlotinib Hydrochloride
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 25, 2017